EurimPharm Arzneimittel GmbH Sustainability Profile
EurimPharm Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe. Founded in 1994, the company has established itself as a trusted provider of high-quality generic medicines and innovative healthcare solutions. EurimPharm focuses on a diverse range of therapeutic areas, including pain management, cardiovascular health, and infectious diseases, offering a portfolio that stands out for its commitment to quality and affordability. With a strong emphasis on research and development, the company has achieved significant milestones, enhancing its market position as a reliable supplier in the competitive pharmaceutical landscape. Recognised for its dedication to patient care and safety, EurimPharm continues to expand its reach, ensuring that effective treatments are accessible to healthcare providers and patients alike.
DitchCarbon Score
How does EurimPharm Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
EurimPharm Arzneimittel GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
EurimPharm Arzneimittel GmbH's reported carbon emissions
EurimPharm Arzneimittel GmbH, headquartered in Germany, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that EurimPharm may not have established formal commitments to reduce carbon emissions or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or commitments from EurimPharm, it is unclear how the company is addressing its environmental impact.
How Carbon Intensive is EurimPharm Arzneimittel GmbH's Industry?
How Carbon Intensive is EurimPharm Arzneimittel GmbH's Location?
EurimPharm Arzneimittel GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
EurimPharm Arzneimittel GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
